The New York Times Exposes How Gilead Devised Egregious Patent Strategy to Extend Monopoly on HIV Treatment, By Delaying Access to “Less Toxic” Version In case you missed it, on Saturday The New York Times published an article exposing how brand name drug maker Gilead employed a greedy patent strategy around a pair of blockbuster […]
Big Pharma Giants Kick Off Q2 Earnings On Heels of July Price Hikes This week, brand name drug makers Novartis and Johnson & Johnson kicked off the first round of Big Pharma earnings reports for the second quarter of 2023. Both Big Pharma giants surpassed Wall Street analysts’ expectations and posted massive profits after having […]
Becerra Encourages Manufacturers to Set “Reasonable” Prices on Upcoming Rounds of COVID-19 Vaccines In case you missed it, on Thursday, U.S. Health and Human Services (HHS) Secretary Xavier Becerra penned a letter to brand name drug makers, urging them to price new COVID-19 vaccines entering the market this year at “a reasonable rate.” The letter follows […]
HHS & CMS Announce New Penalties That Help Hold Brand Name Drug Companies Accountable for Price Hikes Outpacing Inflation In case you missed it, on Monday the U.S. Department of Health and Human Services (HHS) and the U.S. Centers for Medicare & Medicaid Services (CMS) announced new penalties for the third quarter of 2023 on price […]
Physicians Highlight How Big Pharma Games the System to Boost Profits and Block Competition from More Affordable Alternatives On Thursday, an op-ed in The Washington Post from William B. Feldman and Aaron S. Kesselheim, physicians at Brigham and Women’s Hospital and faculty members at Harvard Medical School, highlighted Big Pharma’s extensive patent abuse on brand […]
New Analysis Highlights Urgency to Hold Big Pharma Accountable for Egregious Anti-Competitive Practices Last week, The American Economic Liberties Project and the Initiative for Medicines, Access & Knowledge (I-MAK) released a new analysis examining the staggering cost of Big Pharma’s patent abuse on the U.S. health care system and American patients. The analysis, titled “The […]
Report Finds Big Pharma Games the System to Avoid Paying U.S. Taxes While Price-Gouging American Patients On Thursday, the U.S. Senate Finance Committee held a hearing titled, “Cross-border Rx: Pharmaceutical Manufacturers and U.S. International Tax Policy.” The hearing examined the pharmaceutical industry’s tax practices, in particular, following the passage of the Tax Cuts and Jobs Act of 2017. Ahead […]
Brand Name Drug Giants Refuse to Rule Out Future Insulin Price Hikes On Wednesday, the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) held a hearing with executives from Big Pharma giants Novo Nordisk, Eli Lilly and Sanofi, who control 99 percent of the insulin marketplace. The hearing was titled, “The Need to Make Insulin […]
Lawmakers Have Opportunity to Grill Big Pharma Executives on Tactics Like “Shadow Pricing” that Drove Crisis of Insulin Affordability On Wednesday, the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) will get an opportunity to hold the Big Pharma companies that dominate the insulin market accountable for egregious pricing practices that pushed the […]
Brand Name Drug Companies Continue to Hike Prices and Post Record Profits Rounding out the rest of Big Pharma’s earnings calls for the first quarter, brand name drug makers Pfizer, Moderna, Eli Lilly, Novartis, GlaxoSmithKline, Roche, and Amgen all reported revenue that topped Wall Street expectations, and several of the Big Pharma firms reported stronger […]